References
- Fleich H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–944
- Bauss F, Muehlbauer R C. BM 21.0955, monosodium salt, moonohydrate. Drugs Future 1994; 19: 13–16, No.1
- Delmas P D. Biochemical Markers of Bone Turnover I: Theoretical Considerations and Clinical Use in Osteoporosis. Amer J Med 1993; 95: 11–18, (Suppl. 5A)
- Garnero P, Shih W J, Gineyts E, Karpf D B, Delmas P D. Comparison of New Biochemical Markers of Bone Turnover in Late Postmenopausal Osteoporotic Women in Response to Alendronate Treatment. J Clin Endocrinol Metab 1994; 79: 1693–1700
- Rosalki S B, Foo A Y. Two New Methods for Separating and Quantifying Bone and Liver Alkaline Phosphatase Isoenzymes in Plasma. Clin Chem 1984; 30/7: 1182–1186
- Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Measurement of a more stable structure of osteocalcin in human serum using two monoclonal antibodies in an enzyme-linked immunosorbent assay (ELISA). Clin Chem 1995; 41: 1439–1445
- Bonde M, Qvist, Fledelius C, et al. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem. 1994; 40: 2022–2025
- Garnero P, Gineyts R, Riou J P, Delmas P. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994; 79: 780–785
- Black D, Duncan A, Robins S P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reserved-phase high-performance liquid chromatography. Anal Biochem 1988; 169: 197–203
- Body J J, Clemens M R, Walls J, et al, in preparation
- Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss H J, Body J J. Administration of the Bisphosphonate Ibandronate (BM 21.0955) by Intravenous Bolus Injection. J Bone Min Res 1996; 11, No. 5, May
- Purohit O, Coleman R, Black C, Vinholes J, Kanis J, Schlosser K, Huss H J. Ibandronate: A new oral bisphosphonate for the treatment of bone metastases, Submitted for publication
- Thiébaud D, Kriegbaum H, Huss H, Christiansen C, Burckhard P. Intravenous injections of ibandronate in the treatment of postemenopausal osteoporosis. Osteoporosis 1996. Proceedings of the 1996 World Congress on Osteoporosis, AmsterdamThe Netherlands, May, 18–231996, S E Papapoulos, et al. Elsevier, 321–325
- Rawn P, Clemmesen B, Riis B J, Christiansen C. The Effect on Bone Mass and Bone Markers of Different Doses of Ibandronate: A New Bisphosphonate for Prevention and Treatment of Postmenopausal Osteoporosis: A 1-Year, Randomized, Double-blind, Placebo-Controlled Dose-Finding Study. Bone 1996; 19: 527–533